A Novel CD58 Mutation–Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients

Huili Wang(State Administration of Traditional Chinese Medicine of the People's Republic of China), Wei Xu(University of Auckland), Hua Yin(Nanjing Medical University), Junheng Liang(Jiangsu Province Hospital), Wei Hua(Sichuan University), Li Wang(Beihang University), Xinyu Zhang(First People's Hospital of Yunnan Province), Jianyong Li(Jiangsu Province Hospital), Jia‐Zhu Wu(Augusta University Health), Jin‐Hua Liang(Broad Institute), Yue Li(Nanjing Medical University), Bihui Pan(Jiangsu Province Hospital), Hao-Rui Shen(Nanjing Medical University), Chunyu Shang(Southwest University), Rui Gao(Sichuan University)
Cancer Research and Treatment
July 28, 2025
10.4143/crt.2024.1143
Cited by 2

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study
|Critical Care|2020|450
Interfacial Water Structure Associated with Phospholipid Membranes Studied by Phase-Sensitive Vibrational Sum Frequency Generation Spectroscopy
|Journal of the American Chemical Society|2010|397
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis
|Critical Care|2020|389